A Semax Selank nasal spray combines two peptides—short chains of amino acids—in one liquid delivered through the nose. Both molecules were developed in Russia, where intranasal products established the route people now associate with them. But "nasal spray" is not one fixed formula, and it is not what Promise currently lists: Promise's Semax/Selank product is an injectable vial.
The plain answer is that route matters. A nasal blend should not be treated as interchangeable with Russian drops, a study of either peptide alone, or an injectable blend.
What a Semax Selank nasal spray actually means
Semax and Selank are separate molecules, not two names for one ingredient. Semax is built from part of adrenocorticotropic hormone, a pituitary signal involved in the body's stress response. Selank is a tuftsin analog, a lab-made cousin of an immune-signaling peptide. Semax versus Selank covers that difference; how Semax works and the evidence on Selank for anxiety take the individual research questions further.
A blend simply places both prescribed ingredients in one preparation. It does not tell you the concentration, the chemical form of either peptide, the amount released by the pump, or what else is in the liquid. Those details come from the pharmacy label and the prescription. Formulations vary by pharmacy and prescription.
The Russian history explains the nasal association. A 2022 peer-reviewed paper describes both as registered neuropeptide drugs in the Russian Federation (Yasenyavskaya et al., European Pharmaceutical Journal). FDA's 2026 evidence review identifies registered Russian Semax products as 0.1% and 1% nasal drops. Drops and a metered spray—a pump intended to release a measured volume—are related formats, not identical devices.
That device detail is not trivia. FDA's review called pump delivery, dose uniformity, spray pattern, droplet size, microbial quality, and compatibility between the liquid and container critical features of a nasal product. A bottle labeled with the same two peptide names can still be a different preparation.
Why these peptides were studied through the nose
Peptides are often broken down in the digestive tract, which makes swallowing them a poor route for many molecules. The nasal lining offers another entry point into the bloodstream and, potentially, along the olfactory route—the nerve-lined path from the upper nose toward the brain. Potential is the important word: a nasal spray does not guarantee that a useful amount reaches the brain.
The clearest tracking data here come from animals. In a 2006 rat study, researchers detected radioactively labeled Semax in the brain two minutes after intranasal administration. The amount was small: 0.093% of the introduced radioactivity per gram of brain, and 80% of that signal was intact Semax (Shevchenko et al., Bioorganicheskaia Khimiia, 2006). The peptide then broke down quickly.
A separate 2006 study followed intranasal Selank in rat brain tissue and identified the shorter fragments produced as it degraded (Zolotarev et al., Russian Journal of Bioorganic Chemistry). Together, these studies show why scientists considered the nose plausible. They do not establish human absorption, a human dose, or the effect of a blended spray.
What the human evidence really measured
One small human study placed Semax and Selank in the same experiment, but not in the same treatment. Fifty-two healthy adults received either Semax, Selank, or placebo. Researchers performed resting-state fMRI—a brain scan that tracks activity patterns through blood flow—before dosing and again after 5 and 20 minutes.
The study reported differences in functional connectivity, meaning how activity in different brain regions moves together, around the right amygdala and temporal cortex (Panikratova et al., Doklady Biological Sciences, 2020). It did not measure whether people felt calmer, focused better, remembered more, or benefited clinically. It also did not test a Semax/Selank blend.
That is the honest boundary. Intranasal human studies of the individual peptides help explain why the route became familiar. They cannot be carried over to every U.S. compounded spray, and they do not prove that combining the peptides changes an outcome.
What changed in the U.S. in July 2026
As of September 9, 2026, the day this article was written, FDA's Pharmacy Compounding Advisory Committee reviewed Semax—not Selank—on July 24, 2026, for possible inclusion on the 503A Bulks List, the list of starting ingredients certain traditional compounding pharmacies may use under federal conditions. The official meeting video records an 8–5 vote, with one abstention, to recommend inclusion. FDA's public briefing had proposed not adding Semax, citing gaps in chemical characterization, human pharmacokinetics—how the body absorbs and clears a substance—and safety evidence.
An advisory recommendation is not a drug approval, and the vote did not turn Semax into an FDA-approved medicine. Semax and Selank have no FDA-approved U.S. products. A licensed provider may still prescribe a compounded formulation; that decision is between the patient and the doctor.
Through Promise, the pair is dispensed as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. The current product page lists an injectable vial, so the nasal format discussed in this article is not the route Promise presently describes.
The useful questions before a visit
For any nasal prescription, the details that matter are the exact forms and concentrations of both peptides, how much liquid the pump releases, how the bottle should be stored, and when the pharmacy says it expires. A study using Russian drops does not answer those questions for a different spray.
No published result above supplies a self-directed schedule. The prescriber sets the actual dose, and the dispensing label governs the preparation. The Semax topic archive is the better place for broader reading on the molecule itself.
At Promise, a licensed provider reviews every request and can decline on medical eligibility; not everyone qualifies.